Enitociclib is a small molecule commercialized by Vincerx Pharma, with a leading Phase I program in Primary Mediastinal B-Cell Lymphoma. According to Globaldata, it is involved in 7 clinical trials, of which 1 was completed, 4 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Enitociclib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Enitociclib is expected to reach an annual total of $32 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Enitociclib is under development for the treatment of refractory solid tumor like tumor agnostic MYC aberrations, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, hematological tumor, melanoma, primary mediastinal b-cell lymphoma, gastrointestinal tract cancer, endometrial cancer, ovarian cancer, triple-negative breast cancer, hormone refractory (castration resistant, androgen-independent) prostate cancer, relapsed chronic lymphocytic leukemia (CLL), refractory chronic lymphocytic leukemia (CLL), Richter's syndrome (RS), non-Hodgkin’s lymphoma (NHL), burkitt lymphoma, double-hit diffuse large B-cell lymphoma (DH-DLBCL), multiple myeloma, endometrial, vulva, cervical cancer and various other hematological tumors. It is administered as an intravenous infusion. The drug candidate acts by targeting Cyclin Dependent Kinase 9 (CDK9).
Vincerx Pharma Overview
Vincera Pharma Inc (Vincera), formerly LifeSci Acquisition Corp, is a clinical stage biopharmaceutical company. It discovers and develops therapies for the treatment of cancer. The company’s pipeline product candidates include VIP152, a CDK9 Inhibitor for solid tumors, non-Hodgkin lymphoma and acute myeloid leukemia; VIP236 for the treatment of multiple solid tumors; VIP943, a KSP inhibitor against leukemia’s; VIP924, an antibody-drug conjugate to treat B-cell malignancies. The company is evaluating therapeutics programs for solid and hematologic tumors. Vincera utilizes its proprietary bio conjugate platform to develop therapies in the areas of oncology. Vincera is headquartered in Santa Clara, California, the US.
The operating loss of the company was US$62.7 million in FY2021, compared to an operating loss of US$0.2 million in FY2020. The net loss of the company was US$39.3 million in FY2021, compared to a net loss of US$0.1 million in FY2020.
For a complete picture of Enitociclib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.